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BACKGROUND
Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid exten-
sions, competitively inhibits telomerase enzymatic activity. It has been shown to 
inhibit megakaryocytic proliferation in vitro in cells obtained from patients with 
essential thrombocythemia. In this phase 2 study, we investigated whether ime-
telstat could elicit hematologic and molecular responses in patients with essential 
thrombocythemia who had not had a response to or who had had unacceptable 
side effects from prior therapies.
METHODS
A total of 18 patients in two sequential cohorts received an initial dose of 7.5 or 
9.4 mg of imetelstat per kilogram of body weight intravenously once a week until 
attainment of a platelet count of approximately 250,000 to 300,000 per cubic milli-
meter. The primary end point was the best hematologic response.
RESULTS
Imetelstat induced hematologic responses in all 18 patients, and 16 patients (89%) 
had a complete hematologic response. At the time of the primary analysis, 10 pa-
tients were still receiving treatment, with a median follow-up of 17 months (range, 
7 to 32 [ongoing]). Molecular responses were seen in 7 of 8 patients who were 
positive for the JAK2 V617F mutation (88%; 95% confidence interval, 47 to 100). 
CALR and MPL mutant allele burdens were also reduced by 15 to 66%. The most 
common adverse events during treatment were mild to moderate in severity; neu-
tropenia of grade 3 or higher occurred in 4 of the 18 patients (22%) and anemia, 
headache, and syncope of grade 3 or higher each occurred in 2 patients (11%). All 
the patients had at least one abnormal liver-function value; all persistent elevations 
were grade 1 or 2 in severity.
CONCLUSIONS
Rapid and durable hematologic and molecular responses were observed in patients 
with essential thrombocythemia who received imetelstat. (Funded by Geron; 
ClinicalTrials.gov number, NCT01243073.)
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Imetelstat in Essential Thrombocythemia
Essential thrombocythemia, a myelo-proliferative neoplasm, is a clonal disorder of a multipotent hematopoietic progenitor 
cell.1,2 The disease is associated with an in-
creased risk of thrombotic complications, hemor-
rhagic complications, or both, and can evolve 
into myelofibrosis or, in rare cases, can trans-
form to acute leukemia.3 Common mutations 
associated with essential thrombocythemia are 
found in the Janus kinase 2 (JAK2) gene, the 
gene encoding the thrombopoietin receptor 
(MPL), and the calreticulin (CALR) gene.4-8 Cur-
rent standard therapies for high-risk patients 
with essential thrombocythemia induce nonspe-
cific reductions in platelet counts but do not 
typically eliminate or alter the biologic charac-
teristics of the disease.9-12
We have reported that telomerase activity in 
malignant cells obtained from patients with es-
sential thrombocythemia and induced telomerase 
activity in cells isolated from healthy donors were 
inhibited by the telomerase inhibitor imetelstat.13 
However, imetelstat inhibited spontaneous pro-
liferation of megakaryocytic colonies obtained 
from patients with essential thrombocythemia 
but did not inhibit cytokine-induced megakaryo-
cytic colonies from healthy donors. These find-
ings suggest an intrinsic sensitivity of essential-
thrombocythemia megakaryocytes to telomerase 
inhibition.13
Imetelstat, a 13-mer thiophosphoramidate oli-
gonucleotide that is covalently modified with 
lipid extensions, inhibits telomerase enzymatic 
activity14 (see the Supplementary Background sec-
tion in the Supplementary Appendix, available 
with the full text of this article at NEJM.org). In 
this phase 2 study, we investigated whether im-
etelstat could elicit hematologic and molecular 
responses in patients with essential thrombocy-
themia who had disease that was refractory to 
prior therapies or who had had unacceptable 
side-effects from previous therapies.
Me thods
Eligibility Criteria
Patients who were 18 years of age or older and 
had received a diagnosis of essential thrombocy-
themia defined according to World Health Orga-
nization criteria15 (Table S1 in the Supplemen-
tary Appendix) were eligible for enrollment if 
they required cytoreduction because of a platelet 
count higher than 600,000 per cubic millimeter 
and if they had not had a response to or had had 
unacceptable side effects from at least one prior 
therapy or if they declined to receive standard 
therapy. Additional inclusion and exclusion cri-
teria are described in the Supplementary Ap-
pendix.
Study Design
This was a phase 2, open-label study that was 
conducted at seven sites in the United States, 
Germany, and Switzerland; enrollment occurred 
during the period from January 2010 through 
January 2013. Patients were enrolled into se-
quential cohorts that received weekly doses of 
7.5 or 9.4 mg of imetelstat per kilogram of body 
weight, intravenously, until a platelet count of 
approximately 250,000 to 300,000 per cubic milli-
meter was achieved or toxic effects occurred. 
Maintenance dosing at a reduced frequency be-
gan after a patient had a complete or partial 
hematologic response (Table S2 in the Supple-
mentary Appendix), with doses (7.5 to 11.7 mg 
per kilogram) adjusted according to the patient’s 
response and the side-effect profile of the drug. 
Additional details regarding the study design are 
provided in the Supplementary Appendix.
The primary end point of the study was the 
best overall hematologic response, which was 
defined according to the platelet response com-
ponent of the 2009 European LeukemiaNet (ELN) 
response criteria16 (Table S2 in the Supplemen-
tary Appendix). Secondary end points included 
the frequency and severity of adverse events, the 
duration of hematologic response, the ELN “clin-
icohematologic” response, and the molecular 
response in patients with JAK2 V617F mutations 
(Table S2 in the Supplementary Appendix), MPL 
W515L or MPL W515K mutations, or CALR mu-
tations.
All patients were assessed for JAK2 V617F, 
MPL W515L, MPL W515K, and CALR mutations at 
baseline and were reassessed every 12 weeks 
(±4 weeks) (see the Supplementary Methods sec-
tion in the Supplementary Appendix). Patients 
who were enrolled in Europe underwent testing 
of spontaneous growth inhibition of mega-
karyocyte colony-forming units (CFUs) (see the 
Supplementary Methods section in the Supple-
mentary Appendix).
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Safety Assessment
Data were collected on the extent of imetelstat 
exposure and on all adverse events. Adverse 
events were summarized according to terms used 
in the Medical Dictionary for Regulatory Activities, 
and severity was assessed with the use of the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE),17 version 
4.03. For events with varying severity, the maxi-
mum reported grade was used in summaries. 
Laboratory abnormalities were defined accord-
ing to normal laboratory ranges from each insti-
tution and converted to CTCAE grades.
Study Oversight
This phase 2 study was approved by the institu-
tional review board at each participating site. 
The study was conducted in accordance with the 
International Conference on Harmonisation Good 
Clinical Practice guidelines. All patients provid-
ed written informed consent.
The sponsor, Geron, provided the study drug 
and in collaboration with the authors designed 
the study and analyzed the data. The first author 
wrote the initial draft, and subsequent drafts 
were written by all authors with assistance from 
medical writers paid by Janssen Research and 
Development. All the authors made the decision 
to submit the manuscript for publication and 
vouch for the accuracy and completeness of the 
data and analyses and for adherence to the study 
protocol, which is available at NEJM.org. Clini-
cal-trial agreements between the sponsor and 
the authors’ institutions included confidentiality 
provisions.
Statistical Analysis
The analysis of the primary end point of hema-
tologic response included all patients who re-
ceived at least one dose of imetelstat. The analy-
sis of the duration of response included all 
patients who had a response. The analysis of 
molecular response included patients who re-
ceived at least one dose of imetelstat and who 
had a JAK2 V617F, MPL W515L, MPL W515K, or 
CALR mutant allele burden at baseline. For re-
sponse end points, exact 95% confidence inter-
vals were calculated. The duration of hemato-
logic response was estimated with the use of the 
Kaplan–Meier method. Patients who were lost 
to follow-up, discontinued the study, or began to 
receive other essential thrombocythemia–directed 
therapy before a hematologic response was 
documented and confirmed were counted as not 
having had a response. Safety analyses included 
all patients who received at least one dose of 
imetelstat.
R esult s
Patients
A total of 18 patients were enrolled in the study, 
and all had received one or more previous treat-
ments; 17 had received hydroxyurea (94%), 13 had 
received anagrelide (72%), and 4 had received 
interferon (22%) (Table 1). Nine of the 18 pa-
tients (50%) had disease that was resistant to at 
least one prior therapy, and 14 (78%) had had 
unacceptable side effects from prior therapy. The 
median time from the initial diagnosis of 
 essential thrombocythemia to enrollment was 
7.2 years (range, 0.3 to 24.9), and the median 
baseline platelet count was 788,000 per cubic 
millimeter (range, 521,000 to 1,359,000). Fifteen 
patients had baseline mutant allele burdens 
(8 with JAK2 V617F mutations, 2 with MPL W515L 
or MPL W515K mutations, and 5 with CALR mu-
tations) (Table 1). Table S3 in the Supplementary 
Appendix describes additional baseline charac-
teristics of the patients.
Primary Efficacy End Point and Key Secondary 
Efficacy End Point
Of the 18 patients who received imetelstat, 7 re-
ceived an initial dose of 7.5 mg per kilogram and 
11 received 9.4 mg per kilogram intravenously. 
The overall rate of hematologic response was 
100% (95% confidence interval [CI], 83 to 100), 
and 16 of the 18 patients (89%) had a complete 
hematologic response (95% CI, 65 to 99) (Fig. 1A). 
In the 2 patients with a partial hematologic re-
sponse, the lowest platelet counts were 261,000 
per cubic millimeter at 23 weeks and 56,000 per 
cubic millimeter at 18 weeks, but neither response 
was sustained. Among the 16 patients who had 
a complete hematologic response, the median 
time to a complete response was 6.1 weeks 
(range, 5.1 to 12.1); the median time to a com-
plete response was similar in JAK2 V617F–posi-
tive and JAK2 V617F–negative patients. A trend 
was observed toward a more rapid response in 
patients in whom the initial dose was 9.4 mg per 
kilogram than in those in whom the initial dose 
was 7.5 mg per kilogram (median, 6.1 vs. 12.1 
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weeks), although the difference was not signifi-
cant (P = 0.71).
During maintenance dosing, intermittent dos-
ing was attempted in most patients and the 
frequency of dosing generally decreased with 
time; all the patients who had a complete hema-
tologic response received a dose every 2 weeks 
or less frequently. At the time of the primary 
analysis, with a median follow-up of 17 months, 
10 of the 16 patients with a complete hemato-
logic response (62%) were still receiving treat-
ment, and the median duration of response 
had not been reached (follow-up range, 5 to 30 
months).
While receiving the study treatment, one pa-
tient had grade 2 bilateral retinal ischemia and 
was recovering, and another had grade 2 left 
hemiparesis and recovered; these thromboem-
bolic events were assessed by the study investi-
gators as being potentially related to underlying 
essential thrombocythemia. The durations of 
response ended at the reported onset of these 
conditions, no further clinical follow-up infor-
mation was obtained, and neither patient dis-
continued imetelstat. Three patients had disease 
progression from essential thrombocythemia to 
secondary myelofibrosis, either during the study 
treatment period or during the safety follow-up 
period.
Other Secondary Efficacy End Points
Molecular Response
A partial molecular response was detected in 
seven of eight patients with JAK2 V617F mutations 
at baseline (88%; 95% CI, 47 to 100) (Fig. S1 in 
the Supplementary Appendix). The median JAK2 
V617F mutant allele burden was reduced by 71% 
at month 3 after the initiation of treatment and 
remained reduced by 59% at month 12 despite 
less frequent maintenance dosing (Fig. 1B).
MPL W515L, MPL W515K, and CALR mutant 
allele burdens were also reduced, by 15 to 66%. 
Further information is provided in Table S4 in 
the Supplementary Appendix.
Inhibition of Proliferation
A megakaryocyte CFU assay was performed in 
five patients. It showed substantial inhibition of 
spontaneous proliferation at 1 month after ini-
tiation of imetelstat treatment, with a median 
92% reduction from baseline (Table S5 in the 
Supplementary Appendix).
ELN “Clinicohematologic” Response
Results with respect to the secondary end point 
of a “clinicohematologic” response according to 
ELN criteria16 (see Table S2 of the Supplementary 
Appendix) were similar to those of the primary 
end point. A complete ELN clinicohematologic 
response was observed in 17 of the 18 patients 
(94%), and a partial response was observed in 
1 patient (6%). In 1 patient, splenomegaly that 
was palpable at 3 cm at baseline became nonpal-
pable after the first cycle of treatment. None of 
Variable Patients (N = 18)
Age >60 yr — no. (%) 8 (44)
Sex — no. (%)
Female 10 (56)
Male 8 (44)
Time since initial diagnosis — yr
Median 7.2
Range 0.3–24.9
Platelet count — per mm3*
Median 788,000
Range 521,000–1,359,000
History of thrombosis — no. (%) 5 (28)
Splenomegaly — no. (%) 1 (6)
Bone marrow findings — no. (%)
Reticulin fibrosis: grade 1+ or 2+ 6 (33)
Megakaryocyte hyperplasia 14 (78)
Previous treatment for essential 
 thrombocythemia — no. (%)
Hydroxyurea 17 (94)
Anagrelide 13 (72)
Interferon 4 (22)
>1 prior therapy 13 (72)
Response to previous therapy — no. (%)
Resistant to ≥1 therapy 9 (50)
Unacceptable side effects from ≥1 therapy 14 (78)
Mutation — no. (%)†
JAK2 V617F 8 (44)
MPL W515L or MPL W515K 2 (11)
CALR 5 (28)
*  One patient did not meet the inclusion criteria for the minimum baseline 
platelet count, but the investigator thought that cytoreductive therapy was 
clinically indicated.
†  Three patients had no mutation.
Table 1. Baseline Characteristics of the Patients.
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the 18 patients had constitutional symptoms at 
baseline.
 Telomerase Activity, Telomere Length, 
and Bone Marrow Response
Figure S3 in the Supplementary Appendix shows 
telomerase activity. Assessments of telomere 
length and bone marrow response are described 
in the text of the Supplementary Appendix.
 Safety
The most frequent adverse events that occurred 
during treatment (those that occurred in 50% or 
more of the patients and selected clinically sig-
nificant adverse events) are listed in Table 2. All 
adverse events are listed in Table S6 in the Sup-
plementary Appendix. Adverse events were re-
ported in all patients, and 15 of the 18 patients 
(83%) reported at least one event of grade 3 or 
higher. Eighteen events of grade 3 or higher 
were attributed to imetelstat by the investigators, 
including neutropenia, headache, anemia, and a 
syncopal episode due to an infusion reaction 
(a second syncopal episode in the same patient 
was deemed to be unrelated to imetelstat). One 
grade 4 adverse event (a femoral-neck fracture) 
was reported by the treating clinician as being 
unrelated to imetelstat (Table S6 in the Supple-
mentary Appendix). Eight of the 18 patients 
(44%) discontinued the study (Table S7 in the 
Supplementary Appendix).
The most common nonlaboratory adverse 
events attributed to imetelstat were fatigue (in 15 
of the 18 patients), nausea (in 12), diarrhea (in 11), 
and headache (in 8) (Table S8 in the Supplemen-
tary Appendix). Infections occurred during treat-
ment in 17 of the 18 patients (94%); 15 of these 
17 patients (88%) had infections of grade 2 or 
lower. The most common infections were upper 
respiratory infections (in 39% of the patients), 
urinary tract infections (in 22%), and influenza 
(diagnosed on the basis of clinical and labora-
tory findings), nasopharyngitis, and rash (each 
in 17%). The infections lasted less than 3 weeks 
in 81% of the patients and were not typically as-
sociated with cumulative imetelstat exposure or 
with concurrent neutropenia or lymphopenia.
At least one increase in grade, from baseline, 
in a liver-function value was observed in all 18 
patients (Table 3). The majority of patients had 
grade 1 increases in alanine aminotransferase 
levels, with accompanying grade 1 increases in 
aspartate aminotransferase levels (the latter per-
Figure 1. Hematologic and Molecular Responses in Patients Who Received 
Imetelstat.
Panel A shows the hematologic response according to mutation status (cal-
reticulin [CALR], Janus kinase 2 [ JAK2] V617F, MPL W515L or MPL W515K 
mutations, or no mutation). A complete hematologic response was observed 
in 16 of the 18 patients in the study (89%), and a partial hematologic response 
(“no complete response”) was observed in 2 patients (11%). The median 
time to a complete hematologic response was 1.4 months. Percentages 
shown are the best percent change in the mutant allele burden from base-
line. Panel B shows the molecular response in JAK2 V617F–positive patients 
after treatment with imetelstat. The median JAK2 V617F mutant allele bur-
den was reduced by 71% at month 3 and by 59% at month 12 despite less 
frequent maintenance dosing. I bars indicate 95% confidence intervals. The 
percent change shown is the median percent change in the JAK2 V617F 
mutant allele burden from baseline.
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sisted with ongoing imetelstat treatment). With-
in 4 weeks after the initiation of imetelstat treat-
ment, a transient increase in the alanine 
aminotransferase level of 5 to 7 times the stan-
dard upper limit of the normal range (grade 3) 
and concurrent increases in the aspartate ami-
notransferase level of 2 to 6 times the standard 
upper limit of the normal range (grades 1 to 3) 
were observed. These abnormalities resolved 
with dose reduction and did not recur with con-
tinued treatment. With a longer duration of 
treatment, persistent (≥6 weeks) grade 1 in-
creases in alkaline phosphatase levels were ob-
served in 14 of the 18 patients; these increases 
were associated with grade 1 or 2 unconjugated 
hyperbilirubinemia in 4 patients (Table 3).
In post-study follow-up safety assessments, 
among the 14 patients who had persistent (≥6 
weeks) abnormalities in liver-function values, 11 
(79%) had values that reversed to normal or 
baseline values. In 3 patients, the liver-function 
values did not return to the upper limit of the 
normal range; all hepatic biochemical abnor-
malities in 2 of these patients improved, with 
complete resolution of the abnormal values, and 
the 1 remaining patient whose condition was 
not improving at the end of follow-up had pro-
gression to secondary myelofibrosis. Among 
patients who underwent extended follow-up for 
persistent (≥6 weeks) abnormalities on liver-
function tests, the median time to resolution 
after discontinuation of treatment was 12 weeks. 
The observed resolutions of these abnormalities 
followed permanent discontinuation of ime-
telstat in all patients as the result of a full clini-
cal hold issued by the Food and Drug Adminis-
tration (FDA) (see the Discussion section).
After the primary analysis was performed in 
October 2013, one patient who had received im-
etelstat for approximately 3 years died from 
bleeding esophageal varices approximately 2 
months after discontinuation of treatment. Cir-
rhosis, secondary to hepatic steatosis, was the 
suspected underlying disease. Although the pa-
tient’s age (83 years), multiple coexisting condi-
tions (including a history of exposure to hepati-
tis B), and concomitant medications confounded 
assessment, imetelstat could not be conclusively 
excluded as a contributory agent.
Hematologic toxic effects, defined according 
to changes in laboratory results from baseline 
values, are listed in Table 4. Thrombocytopenia 
of less than grade 3 was seen in 9 of the 18 pa-
tients (50%). Neutropenia was observed in 15 pa-
tients (83%), including 7 with grade 3 neutrope-
nia (39%) and 3 with grade 4 neutropenia (17%). 
Event All Grades Grade 3 or 4
number of patients (percent)
Fatigue 15 (83) 1 (6)
Diarrhea 14 (78) 0
Nausea 13 (72) 0
Dizziness 11 (61) 0
Increased alanine aminotransferase 
level
10 (56) 1 (6)
Increased aspartate aminotransferase 
level
10 (56) 1 (6)
Constipation 9 (50) 0
Cough 9 (50) 0
Epistaxis 9 (50) 1 (6)
Headache 9 (50) 2 (11)
Decreased neutrophil count 7 (39) 4 (22)
Anemia 6 (33) 2 (11)
Upper respiratory tract infection 6 (33) 1 (6)
Decreased white-cell count 6 (33) 1 (6)
Myalgia 4 (22) 1 (6)
Neutropenia 4 (22) 4 (22)
Hypokalemia 4 (22) 1 (6)
Syncope 3 (17) 2 (11)
Cellulitis 3 (17) 1 (6)
*  Included are the adverse events that occurred in 50% or more of the patients 
and selected clinically significant adverse events, regardless of whether they 
were deemed to be related to the study drug. The grade of adverse event was 
defined on the basis of the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE).
Table 2. Frequent Adverse Events among the 18 Patients Enrolled  
in the Study.*
Analyte Grade 1 Grade 2 Grade 3
number of patients (percent)
Alanine aminotransferase 13 (72) 2 (11) 2 (11)
Aspartate aminotransferase 15 (83) 1 (6) 1 (6)
Alkaline phosphatase 14 (78) 1 (6) 0
Total bilirubin 2 (11) 4 (22) 0
*  Laboratory abnormalities were defined on the basis of normal laboratory rang-
es at each institution and were graded according to the CTCAE. The maximum 
grade was calculated for patients who had an increase in grade, as compared 
with the baseline grade. There were no grade 4 increases.
Table 3. Liver-Enzyme Levels in 18 Patients with Essential 
Thrombocythemia.*
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No cases of febrile neutropenia were reported, 
and no patients with grade 4 neutropenia had a 
concurrent infection. Lymphopenia was reported 
in 6 patients (33%), with one grade 3 event. Fif-
teen patients (83%) had anemia, and 3 (17%) had 
grade 3 anemia. Three patients required red-cell 
transfusions, including a patient who had a 
postsurgical hemorrhage. Three reported cases 
of cytopenia led to dose reductions: one for 
grade 1 thrombocytopenia, one for grade 3 ane-
mia in a patient who required a red-cell transfu-
sion, and one for grade 3 neutropenia; all three 
cases resolved.
Discussion
In this study, imetelstat rapidly induced hemato-
logic responses in patients with essential throm-
bocythemia who had disease that was refractory 
to conventional therapies or who had had unac-
ceptable side effects from conventional therapies. 
All the patients had a hematologic response, and 
89% had a complete hematologic response, a rate 
that exceeded rates observed with hydroxyurea, 
anagrelide, and interferon treatment.12,18-21 Else-
where in this issue of the Journal, Tefferi et al. 
report the results of a pilot study of imetelstat 
therapy showing the induction of complete or 
partial remissions, as well as molecular remis-
sions, in a subgroup of patients with myelofi-
brosis.22
JAK2 V617F may provide a useful marker of 
neoplastic proliferation, and current therapies 
elicit molecular responses in only a minority of 
patients with this mutation.12,20,23,24 In contrast, 
a rapid, substantial reduction in mutant allele 
burden was observed in all JAK2 V617F–positive 
patients in this study; 88% of patients had a 
partial molecular response. Attenuation and loss 
of a molecular response later during therapy may 
be due in part to reduced-frequency maintenance 
dosing; this suggests that the duration of ime-
telstat treatment was insufficient to eliminate all 
mutated committed and clonal primitive hema-
topoietic progenitors. The decrease in the CALR 
and MPL mutant allele burdens provides support 
for the hypothesis that imetelstat can reduce the 
various malignant clones observed in myelopro-
liferative neoplasms. The decrease in the mutant 
allele burden appeared to be more pronounced 
for the JAK2 V617F mutations than for the CALR 
mutations, possibly because of activation of 
telomerase reverse transcriptase by the Janus 
kinase–signal transducer and activator of tran-
scription (JAK-STAT) signaling pathway in pa-
tients with essential thrombocythemia who had 
JAK2 V617F mutations.25,26
Megakaryocyte CFU assays that were used to 
more directly measure inhibition of proliferation 
showed more than 90% inhibition of baseline 
proliferation activity within 1 month after the 
initiation of treatment in four of the five patients 
tested. These data suggest that imetelstat may 
have a selective inhibitory effect on the growth 
of the neoplastic clone or clones that drive es-
sential thrombocythemia.
Although all the patients had hematologic 
responses, there were subsequent f luctuations 
above normal platelet levels in all patients. Re-
sponses were considered to be durable if inter-
mittent dosing restored and maintained the 
platelet count (≤600,000 per cubic millimeter for 
a partial response or ≤400,000 per cubic milli-
meter for a complete response). Once an initial 
response was achieved, patients with platelet 
counts that were not controlled by maintenance 
dosing (i.e., platelet counts that were >600,000 
per cubic millimeter in patients with a partial 
response or >400,000 per cubic millimeter in 
patients with a complete response) for at least 
8 weeks were considered to have a loss of re-
sponse. The reported complete hematologic re-
sponses were durable but required ongoing ime-
telstat therapy; interpatient variability was noted 
in the frequency of dosing required to manage 
platelet levels (every 2 weeks to every 4 weeks or 
more) (Fig. S2 in the Supplementary Appendix).
Effect All Grades Grade 3 Grade 4
number of patients (percent)
Neutropenia 15 (83) 7 (39) 3 (17)
Thrombocytopenia 9 (50) 0 0
Anemia 15 (83) 3 (17) 0
Leukopenia 16 (89) 5 (28) 0
Lymphopenia 6 (33) 1 (6) 0
*  Laboratory abnormalities were defined on the basis of normal laboratory rang-
es at each institution and were graded according to the CTCAE. The maxi-
mum grade was calculated for patients who had an increase in grade, as com-
pared with the baseline grade.
Table 4. Hematologic Toxic Effects among 18 Patients Who Received 
Imetelstat.*
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After discontinuation of treatment, increases 
in platelet counts were consistent with the main-
tenance interval during treatment. Patients with 
longer treatment intervals had more gradual 
increases after discontinuation of treatment, 
whereas patients who required more frequent 
dosing had more rapid increases.
At the time of the primary analysis, 10 pa-
tients were still receiving treatment, with a 
median follow-up of 17 months (range, 7 to 32 
[ongoing]). Of the adverse events attributed to 
imetelstat, most were mild to moderate; 18 events 
were of grade 3 or higher (Table S8 in the Sup-
plementary Appendix). Upper respiratory infec-
tions, which were reported in 6 of 18 patients 
(33%), were mostly mild to moderate and were 
not associated with myelosuppression or disease 
progression. Three patients had disease progres-
sion from essential thrombocythemia to second-
ary myelofibrosis, either during the study treat-
ment period or during the safety follow-up 
period, and JAK inhibitor therapies were initiat-
ed. Among these 3 patients, one had an unrelated 
grade 2 upper respiratory tract infection and 
grade 3 osteomyelitis and another had grade 2 
influenza.
In a study involving 1104 patients, the rates 
of progression from essential thrombocythemia 
and from early or prefibrotic primary myelofi-
brosis to overt myelofibrosis were 0.8% and 
12.3%, respectively, at 10 years and 9.3% and 
16.9%, respectively, at 15 years.26 The prognostic 
variables associated with death or progression to 
leukemia or myelofibrosis were bone marrow 
histologic features (early or prefibrotic primary 
myelofibrosis vs. essential thrombocythemia), 
age (>60 years), history of thrombosis, leukocy-
tosis, and anemia.27 The 3 patients in our study 
who had disease that progressed to myelofibro-
sis had essential thrombocythemia for 12, 13, 
and 21 years and were 67, 61, and 56 years old, 
respectively, when myelofibrosis was diagnosed. 
Two of the 3 patients received the diagnosis 
near the date of their last dose of imetelstat, and 
1 received the diagnosis 6 months after the last 
dose, during extended follow-up of liver func-
tion. At baseline, 2 of the 3 patients had 1+ and 
2+ reticulin fibrosis in the bone marrow, and the 
hemoglobin level in all 3 patients was lower 
than 12 g per deciliter. The rate of progression 
to myelofibrosis in the current study (17%; 3 of 
18 patients) is higher than historical estimates; 
however, the small number of patients in this 
study and the presence of prognostic factors 
make cross comparisons difficult.
Abnormal results of liver-function tests were 
observed frequently but were mostly mild in 
grade; one fatal event of bleeding esophageal 
varices occurred after the primary-analysis time 
point. On March 11, 2014, the FDA issued a full 
clinical hold on imetelstat, citing a lack of evi-
dence of reversibility of hepatotoxicity, concern 
regarding a risk of chronic liver injury, and a 
lack of adequate follow-up in patients who had 
hepatotoxic effects. All the patients who were 
still receiving the study medication permanently 
discontinued active treatment and were observed 
for safety. Follow-up safety data showed that 
treatment-related abnormalities on liver-function 
tests resolved in most patients (Table S9 in the 
Supplementary Appendix), and the FDA lifted 
the clinical hold on October 31, 2014.
In conclusion, imetelstat, a telomerase inhibi-
tor, had a clinically significant effect on disease 
burden in patients with essential thrombocythe-
mia who had not had a response to previous 
treatment or who had had unacceptable side ef-
fects from conventional therapies. Neutropenia 
and abnormal liver-function tests were the main 
adverse events. Furthermore, molecular respons-
es were observed in patients with mutated JAK2 
and CALR molecular signatures; this finding 
suggests therapeutic activity in the malignant 
clones that are the underlying source of essential 
thrombocythemia.
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